Accessibility Menu
Revvity logo

Revvity(NYSE) RVTY

Market Cap$13.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1968)+7,455%
5 Year-33%
1 Year+31%
1 Month+12%
$123.72
+3.57%
+4.27Today
Revvity last closing stock price
MetricPriceDate
Last closeUSD 119.452026-08-19
Revvity stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.33%USD 117.882026-08-12
1 month+12.22%USD 106.442026-07-20
3 month+25.31%USD 95.322026-05-21
Year to date+23.71%USD 96.562025-12-31
1 year+31.02%USD 91.172025-08-19
3 year+6.36%USD 112.312023-08-18
5 year-33.25%USD 178.952021-08-20
Since inception+7,455.42%USD 1.581968-01-02

Revvity Financials at a Glance

Market Cap

$13.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.91B

Net Income (TTM)

$237.55M

EPS (TTM)

$2.11

P/E Ratio

56.73

Dividend

$0.28

Beta (Volatility)

1.05 (Average)

Price

$123.72

Volume

414,995.64

Open

$118.26

Previous Close

$119.45

Daily Range

$116.96 - $123.55

52-Week Range

$81.22 - $123.55

Estimated Earnings Date

Oct 26, 2026

RVTY News

Foolcom-Featured.png

Revvity Q2 Revenue Up 4 Percent

Motley Fool Markets TeamJul 28, 2025
woman lab science research STEM

Why Revvity Stock Plunged Today

Steve SymingtonOct 30, 2023
GettyImages-1193695668

Why Shares of PerkinElmer Dropped 14.4% in January

James HalleyFeb 7, 2022
IRS building sign and stoplight Internal Revenue Service headquarters

3 Strong Stocks for Your Income Tax Return

James HalleyMay 25, 2021
COVID test

How PerkinElmer Beat Expectations in Q4

Keith SpeightsFeb 3, 2021
research scientists drugs pharma biotech (1)

Why Is Nobody Talking About PerkinElmer Stock?

James HalleyJan 5, 2021
GettyImages-1212780825

The FDA Just Ranked Coronavirus Tests by Sensitivity. Here's What That Means

Alex CarchidiOct 3, 2020
Coronavirus positive test

FDA Evaluates 5 More COVID-19 Antibody Tests

Brian Orelli, PhDJun 5, 2020
Page 1

RVTY: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Revvity

Revvity, Inc. makes tools for finding and treating diseases. These products help doctors test health in newborn babies. The company also builds software to track medical research.

Tools for Testing and Research

  • Diagnostics: Tools and reagents for identifying genetic disorders and infectious diseases; generated $371.0 million in revenue in the second quarter of fiscal year 2026.
  • Life Sciences: Instruments and imaging technologies for drug discovery research; accounted for $358.7 million in revenue in the second quarter of fiscal year 2026.
  • Reproductive Health: Screening solutions for conditions like Down syndrome and metabolic disorders; drove growth in the Diagnostics segment.
  • Software and Informatics: Digital tools and subscriptions used to manage complex scientific research workflows and data analysis.

Strategic Moves and Streamlining

  • Renamed the business from PerkinElmer, Inc. in April 2023 to align with a focused health science strategy.
  • Spent $67.1 million on acquisitions during the six-month period ended July 5, 2026.
  • Launched restructuring actions that affected approximately 5% of its workforce during the first half of fiscal year 2026.
  • Applied for $20.2 million in tariff refunds following a 2026 United States Supreme Court ruling.

Connecting Lab to Clinic

Revvity serves a broad range of clients from pharmaceutical firms to public health authorities. Its offerings provide end-to-end support from early lab discovery to final patient diagnosis.

Checking the Books

  • Overall revenue for the three-month period ended July 5, 2026 was $729.7 million, up 1% year over year.
  • Gross margin increased to 57.1% for the three-month period ended July 5, 2026, up 260 basis points year over year.
  • Net cash provided by operating activities reached $317.8 million for the six-month period ended July 5, 2026, up $49.4 million from the prior year.
  • Market capitalization reached $12.6 billion in the second quarter of 2026, up 11.0% year over year.
  • The price-to-earnings ratio was 60.1 in the second quarter of 2026, up 16.8% year over year.

Bottom Line

Revvity has transformed from a broad industrial supplier into a focused health science technology provider. Its specialization in diagnostics and life science workflows maintains its relevance in modern medical research.

AI Generated • Aug 12, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

11,000

CEO

Prahlad Ramadhar Singh, PhD, MBA

Website

www.revvity.com

Headquarters

Waltham, MA 02451, US

RVTY Financials

Key Financial Metrics (TTM)

Gross Margin

52.11%

Operating Margin

12.32%

Net Income Margin

8.16%

Return on Equity

3.27%

Return on Capital

3.31%

Return on Assets

1.97%

Earnings Yield

1.76%

Dividend Yield

0.23%

Payout Ratio

13.36%

Stock Overview

Market Cap

$13.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

111.59M

Volume

415.00K

Avg. Volume

1.49M

Financials (TTM)

Gross Profit

$1.52B

Operating Income

$358.85M

EBITDA

$767.00M

Operating Cash Flow

$628.86M

Capital Expenditure

-$69.52M

Free Cash Flow

$559.34M

Cash & ST Invst.

$1.02B

Total Debt

$3.34B

Revvity Performance Analysis

Revvity annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,311,822,000-13.5%
20232023-12-31USD 2,750,571,000-16.9%
20242024-12-31USD 2,755,026,0000.2%
20252025-12-31USD 2,856,051,0003.7%
Revvity sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-28-3.0%
Q42025-12-2810.5%
Q12026-04-05-7.9%
Q22026-07-052.6%
Revvity annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 4.50-44.3%
20232023-12-31USD -0.95N/A
20242024-12-31USD 2.41N/A
20252025-12-31USD 2.08-13.8%
Revvity sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-28-14.9%
Q42025-12-28117.5%
Q12026-04-05-58.6%
Q22026-07-0530.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$729.69M

+1.3%

Gross Profit

$416.87M

+6.2%

Gross Margin

57.13%

N/A

Market Cap

$13.33BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.21M

N/A

Employees

11,000

N/A

Net Income

$51.82M

-6.2%

EBITDA

$188.56M

-3.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.02B

+3.1%

Total Debt

$3.34B

-1.0%

Accounts Receivable

$709.18M

+7.3%

Inventory

$378.50M

-2.6%

Long Term Debt

$2.77B

-17.9%

Short Term Debt

$572.16M

+248663.5%

Return on Assets

1.97%

N/A

Return on Invested Capital

3.33%

N/A

Free Cash Flow

$180.87M

+56.7%

Operating Cash Flow

$191.94M

+42.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ICLRICON Public Limited Company
$179.95+4.33%
CRLCharles River Laboratories International, Inc.
$299.23+3.18%
ALGNAlign Technology, Inc.
$158.57-2.74%
SOLVSolventum Corporation
$88.56+0.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.77+0.06%
IBITiShares Bitcoin Trust
$40.92+0.06%
SPCXSpace Exploration Technologies
$130.55-0.07%
MRNAModerna
$139.48-0.20%

Questions About RVTY

What is the current price of Revvity?

Revvity is trading at $123.04 per share.

What is the 52-week range for Revvity?

Over the past 52 weeks, Revvity has traded between $81.22 and $123.55.

How much debt does Revvity have?

As of the most recent reporting period, Revvity reported total debt of $3.34B.

How much cash does Revvity have on hand?

Revvity reported $1.02B in cash and cash equivalents in its most recent financial results.

What is Revvity’s dividend yield?

Revvity currently has a dividend yield of 0.23%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services